Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Date of Report: February 29, 2024
Reporting Period: Fourth Quarter and Full Year ended December 31, 2023
Business Overview: The Company is a Delaware corporation focused on therapeutic development, with principal executive offices in San Diego, California. This filing announces the release of financial results for the specified period.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the detailed financial data but does not include the specific numerical values within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific financial figures are contained in the attached Exhibit 99.1 (Press Release), which is not included in the input source text.
Material Changes
The filing text does not provide specific data to compare current period performance against prior comparable periods. It only confirms that results for the quarter and full year ended December 31, 2023, have been announced.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that the Company issued a press release titled "Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update." This suggests the press release contains corporate updates and potentially forward-looking statements, but the content of those statements is not present in this document.
Risks and Contingencies: No specific risks or contingencies are detailed in this text. The filing includes a standard disclaimer that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (the Press Release) for specific revenue, net loss, and cash position figures for Q4 and Full Year 2023.
- Verify the "Corporate Update" section in the press release for details on clinical trial progress or pipeline milestones.
- Check for any updated financial guidance or cash runway projections mentioned in the press release.
- Confirm the status of the Company's emerging growth company election (indicated as elected not to use the extended transition period in this filing).